This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Injury Prevention & Control  • Public Health, Other  • Informatics/ Internet in Medicine  • Informatics, Other  • Adverse Effects  • Alert me on articles by topic

Donald F. Klein, MD; Charles P. O'Brien, MD, PhD

JAMA. 2007;298:333-334.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Public concern about serious toxicities from marketed drugs approved by the US Food and Drug Administration (FDA) has led to suspicion of both the pharmaceutical industry and the FDA.¹ This has caused the FDA to issue severe, black-box warnings about antidepressant use; however, this action may have been taken based on inadequate grounds.²

The central problem is that the current faulty system cannot even detect rare but severe toxicities nor can it detect those that appear late in the use of medication or those that occur during off-label use.³ Furthermore, premarketing clinical trials do not address issues related to possible toxicities due to drug interactions or comorbid illnesses. It is often not recognized that there is no basis from information gained in clinical trials for the original indications that lead to legal off-label use for other indications, nor is the pharmaceutical . . . [Full Text of this Article]

Computer-Based Pharmacoepidemiology

Author Affiliations: Department of Psychiatry, Columbia University, New York, New York (Dr Klein); Department of Psychiatry, University of Pennsylvania and Philadelphia VA Medical Center (Dr O'Brien).

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Overcoming the current approach in bipolar disorder research: towards DSM-V and beyond
Vieta
J Psychopharmacol 2008;22:406-407.